logo
Plus   Neg
Share
Email

Roche's Entrectinib Shrinks Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions

Swiss drug major Roche (RHHBY) said that its investigational medicine Entrectinib shrank tumours in all 11 children and adolescents who had neurotrophic tyrosine receptor kinase, ROS1 or anaplastic lymphoma kinase fusion-positive solid tumours in a phase I/II study, dubbed STARTRK-NG. Complete responses were observed in 2 patients with tumours harbouring NTRK and ALK fusions.

In the study, of the 11 patients, five patients with primary high-grade tumours in the central nervous system or CNS had an objective response, including one patient with a complete response.

"We are encouraged by the results we have seen with Entrectinib in children with paediatric and adolescent cancers, including those with tumours in the brain," said Sandra Horning, Roche's Chief Medical Officer and Head of Global Product Development.

The safety profile of Entrectinib was consistent with that seen in previous analyses, the company said.

Entrectinib for both the treatment of paediatric and adult patients with NTRK fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic ROS1-positive NSCLC is under priority review by the FDA.

The FDA expects to make a decision on approval by August 18, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Crate and Barrel have recalled 1,500 push walkers due to risk of choking and laceration. Crate and Barrel have recalled Activity Push Walkers as those walkers can be damaged over time exposing sharp points and small parts, posing choking and laceration hazards to small children. The wooden recalled... YouTube is finalizing plans under which it will no longer serve "targeted" advertisements on its main site for videos meant for kids, Bloomberg reported, citing people familiar with the discussion. While the plan is reportedly intended to satisfy U.S. regulators, it could negatively impact the Google-owned video giant's ad sales as kids' content on YouTube is immensely popular. Apple Inc. (AAPL) is in the final stages of certifying advanced flexible Organic Light Emitting Diode or OLED screens from Chinese display maker BOE Technology Group for iPhones next year, the Nikkei Asian Review reported citing source. The U.S. tech giant has been attempting to reduce reliance on Samsung Electronics of South Korea.
Follow RTT